EPM conducted a roundtable with several pharma experts to learn what industry trends to watch out for in 2023, from AI drug discovery through to the rise of decentralised trials.
Tim Guilliams, CEO and co-founder, Healx:
"Thanks to improvements in software and computing, the field of drug discovery is being completely reimagined with life changing effects for the hundreds of millions of people living with rare diseases worldwide. In 2023 we will increasingly see AI used across the entire drug discovery and development pipeline. From de novo design of molecules and treatment combination predictions, to preclinical validation, right up to the running of clinical trials for precision medicine. We will also see greater collaboration between industry, technologists, academics and patient groups to progress more novel rare disease treatments towards clinical trials."